CytomX Therapeutics, Inc. — Insider Transactions
Form 4 filings by directors, officers, and 10%+ shareholders
SEC rules require corporate insiders — including directors, executive officers, and any shareholder owning more than 10% of a company's shares — to report changes in their ownership within two business days of a transaction. These disclosures are filed as Form 4. Open-market purchases (code P) are generally considered the most meaningful signal, as insiders are spending their own money.
| Insider | Title | Type | Shares | Price | Value | Owns After | Date |
|---|---|---|---|---|---|---|---|
| McCarthy Sean A. | CEO | Sale | 101,793 | $4.54 | $462,140 | 987,891 | Nov 6, 2025 |
| McCarthy Sean A. | CEO | Option Exercise | 150,000 | — | — | 1,145,195 | Jun 16, 2025 |
| Ogden Christopher | Chief Financial Officer | Sale | 1,641 | $2.95 | $4,841 | 199,385 | Jun 13, 2025 |
| BELVIN MARCIA | SVP, Chief Scientific Officer | Sale | 13,884 | $2.69 | $37,348 | 272,252 | Jun 13, 2025 |
| McCarthy Sean A. | CEO | Sale | 37,656 | $0.60 | $22,594 | 995,195 | Mar 18, 2025 |
| Ogden Christopher | Chief Financial Officer | Sale | 8,551 | $0.60 | $5,131 | 201,026 | Mar 18, 2025 |
| Chu Yu-Waye | Chief Medical Officer | Sale | 4,025 | $0.60 | $2,415 | 135,725 | Mar 18, 2025 |
| ROWLAND LLOYD A | General Counsel | Sale | 10,203 | $0.60 | $6,122 | 120,594 | Mar 18, 2025 |
| BELVIN MARCIA | SVP, Chief Scientific Officer | Sale | 19,512 | $0.60 | $11,707 | 248,636 | Mar 18, 2025 |
| BELVIN MARCIA | SVP, Chief Scientific Officer | Award / Grant | 35,000 | — | — | 210,648 | Feb 4, 2025 |
| BELVIN MARCIA | SVP, Chief Scientific Officer | Award / Grant | 57,500 | — | — | 263,148 | Feb 4, 2025 |
| Chu Yu-Waye | Chief Medical Officer | Award / Grant | 56,000 | — | — | 82,250 | Feb 4, 2025 |
| Ogden Christopher | Chief Financial Officer | Award / Grant | 57,500 | — | — | 209,577 | Feb 4, 2025 |
| McCarthy Sean A. | CEO | Award / Grant | 180,000 | — | — | 837,851 | Feb 4, 2025 |
| Landau Jeffrey B | Chief Business Officer | Sale | 4,181 | $1.23 | $5,143 | 119,056 | Aug 20, 2024 |
| BELVIN MARCIA | SVP, Chief Scientific Officer | Sale | 4,181 | $1.23 | $5,143 | 175,648 | Aug 20, 2024 |
| ROWLAND LLOYD A | General Counsel | Sale | 4,181 | $1.23 | $5,143 | 130,797 | Aug 20, 2024 |
| Ogden Christopher | Chief Financial Officer | Sale | 1,984 | $1.23 | $2,440 | 108,077 | Aug 20, 2024 |
| McCarthy Sean A. | CEO | Option Exercise | 37,500 | — | — | 671,749 | Aug 20, 2024 |
| Ogden Christopher | Chief Financial Officer | Award / Grant | 17,500 | — | — | 103,186 | Jun 12, 2024 |
| McCarthy Sean A. | CEO | Option Exercise | 109,768 | $1.57 | $172,336 | 634,249 | Mar 26, 2024 |
| ROWLAND LLOYD A | General Counsel | Sale | 5,268 | $2.09 | $11,010 | 117,728 | Mar 19, 2024 |
| McCarthy Sean A. | CEO | Sale | 20,223 | $2.09 | $42,266 | 524,481 | Mar 19, 2024 |
| Ogden Christopher | SVP, Finance and Accounting | Sale | 2,971 | $2.09 | $6,209 | 85,686 | Mar 19, 2024 |
| BELVIN MARCIA | SVP, Chief Scientific Officer | Sale | 12,795 | $2.09 | $26,742 | 168,579 | Mar 19, 2024 |
| Landau Jeffrey B | Chief Business Officer | Sale | 6,562 | $2.09 | $13,715 | 110,060 | Mar 19, 2024 |
| McCarthy Sean A. | CEO | Award / Grant | 90,000 | — | — | 544,704 | Jan 18, 2024 |
| ROWLAND LLOYD A | General Counsel | Award / Grant | 25,000 | — | — | 122,996 | Jan 18, 2024 |
| Ogden Christopher | SVP, Finance and Accounting | Award / Grant | 40,000 | — | — | 88,657 | Jan 18, 2024 |
| Landau Jeffrey B | Chief Business Officer | Award / Grant | 30,000 | — | — | 116,622 | Jan 18, 2024 |
| BELVIN MARCIA | SVP, Chief Scientific Officer | Award / Grant | 26,250 | — | — | 181,374 | Jan 18, 2024 |
| Chu Yu-Waye | Chief Medical Officer | Award / Grant | 26,250 | — | — | 26,250 | Jan 18, 2024 |
| McCarthy Sean A. | CEO | Sale | 13,551 | $1.38 | $18,700 | 454,704 | Dec 20, 2023 |
| BELVIN MARCIA | SVP, Chief Scientific Officer | Sale | 4,077 | $1.38 | $5,626 | 155,124 | Dec 20, 2023 |
| Landau Jeffrey B | Chief Business Officer | Sale | 4,077 | $1.38 | $5,626 | 86,622 | Dec 20, 2023 |
| ROWLAND LLOYD A | General Counsel | Sale | 4,077 | $1.38 | $5,626 | 97,996 | Dec 20, 2023 |
| Ogden Christopher | SVP, Finance and Accounting | Sale | 1,990 | $1.38 | $2,746 | 48,657 | Dec 20, 2023 |
| Ogden Christopher | SVP, Finance and Accounting | Option Exercise | 6,875 | — | — | 50,647 | Dec 17, 2023 |
| McCarthy Sean A. | CEO | Option Exercise | 37,500 | — | — | 468,255 | Dec 17, 2023 |
| Landau Jeffrey B | Chief Business Officer | Option Exercise | 11,250 | — | — | 90,699 | Dec 17, 2023 |
| ROWLAND LLOYD A | General Counsel | Option Exercise | 11,250 | — | — | 102,073 | Dec 17, 2023 |
| BELVIN MARCIA | SVP, Chief Scientific Officer | Option Exercise | 11,250 | — | — | 159,201 | Dec 17, 2023 |
| BELVIN MARCIA | SVP, Chief Scientific Officer | Award / Grant | 11,250 | — | — | 152,070 | Sep 22, 2023 |
| ROWLAND LLOYD A | General Counsel | Award / Grant | 15,000 | — | — | 86,095 | Sep 22, 2023 |
| Landau Jeffrey B | Chief Business Officer | Sale | 4,119 | $1.30 | $5,355 | 76,379 | Sep 20, 2023 |
| McCarthy Sean A. | CEO | Sale | 14,601 | $1.30 | $18,981 | 430,755 | Sep 20, 2023 |
| McCarthy Sean A. | CEO | Option Exercise | 16,535 | $1.57 | $25,960 | 405,356 | May 19, 2023 |
| Jones Elaine V | — | Purchase | 5,000 | $1.55 | $7,750 | 5,142 | Mar 29, 2023 |
| BELVIN MARCIA | SVP, Chief Scientific Officer | Award / Grant | 60,000 | — | — | 140,820 | Mar 22, 2023 |
| Ogden Christopher | SVP, Finance and Accounting | Sale | 516 | $1.98 | $1,022 | 37,772 | Mar 16, 2023 |